238 related articles for article (PubMed ID: 30394592)
1. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.
Knoop A; Thomas A; Thevis M
Rapid Commun Mass Spectrom; 2019 Feb; 33(4):371-380. PubMed ID: 30394592
[TBL] [Abstract][Full Text] [Related]
2. Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches.
Sigmund G; Koch A; Orlovius AK; Guddat S; Thomas A; Schänzer W; Thevis M
Drug Test Anal; 2014; 6(11-12):1197-205. PubMed ID: 24913825
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.
Thevis M; Schänzer W
Rapid Commun Mass Spectrom; 2016 Mar; 30(5):635-51. PubMed ID: 26842585
[TBL] [Abstract][Full Text] [Related]
4. In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry.
Knoop A; Krug O; Vincenti M; Schänzer W; Thevis M
Eur J Mass Spectrom (Chichester); 2015; 21(1):27-36. PubMed ID: 25906032
[TBL] [Abstract][Full Text] [Related]
5. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
[TBL] [Abstract][Full Text] [Related]
6. Determination of GnRH and its synthetic analogues' abuse in doping control: Small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers.
Zvereva I; Dudko G; Dikunets M
Drug Test Anal; 2018 Apr; 10(4):711-722. PubMed ID: 28777889
[TBL] [Abstract][Full Text] [Related]
7. Determination of LongR
Thomas A; Walpurgis K; Delahaut P; Fichant E; Schänzer W; Thevis M
Growth Horm IGF Res; 2017 Aug; 35():33-39. PubMed ID: 28668757
[TBL] [Abstract][Full Text] [Related]
8. Analysis of seized peptide and protein-based doping agents using four complimentary methods: Liquid chromatography coupled with time of flight mass spectrometry, liquid chromatography-ultraviolet, Bradford, and immunoassays.
Høj LJ; Rasmussen BS; Dalsgaard PW; Linnet K
Drug Test Anal; 2021 Jul; 13(7):1457-1463. PubMed ID: 33686802
[TBL] [Abstract][Full Text] [Related]
9. Expanding analytical options in sports drug testing: Mass spectrometric detection of prohibited substances in exhaled breath.
Thevis M; Krug O; Geyer H; Schänzer W
Rapid Commun Mass Spectrom; 2017 Aug; 31(15):1290-1296. PubMed ID: 28508503
[TBL] [Abstract][Full Text] [Related]
10. Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects.
Ramanjaneya M; Jerobin J; Bettahi I; Bensila M; Aye M; Siveen KS; Sathyapalan T; Skarulis M; Abou-Samra AB; Atkin SL
Clin Endocrinol (Oxf); 2019 Aug; 91(2):278-287. PubMed ID: 31066084
[TBL] [Abstract][Full Text] [Related]
11. Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing.
Schänzer W; Guddat S; Thomas A; Opfermann G; Geyer H; Thevis M
Drug Test Anal; 2013; 5(11-12):810-8. PubMed ID: 23873860
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes.
Höppner S; Delahaut P; Schänzer W; Thevis M
J Pharm Biomed Anal; 2014 Jan; 88():649-59. PubMed ID: 24239904
[TBL] [Abstract][Full Text] [Related]
13. Detection of stanozolol O- and N-sulfate metabolites and their evaluation as additional markers in doping control.
Balcells G; Matabosch X; Ventura R
Drug Test Anal; 2017 Jul; 9(7):1001-1010. PubMed ID: 27714936
[TBL] [Abstract][Full Text] [Related]
14. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.
Bredehöft M; Schänzer W; Thevis M
Rapid Commun Mass Spectrom; 2008; 22(4):477-85. PubMed ID: 18236437
[TBL] [Abstract][Full Text] [Related]
15. Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LC-IM-MS).
Thomas A; Schänzer W; Thevis M
Drug Test Anal; 2014; 6(11-12):1125-32. PubMed ID: 25219675
[TBL] [Abstract][Full Text] [Related]
16. Targeting misuse of 2-amino-N-ethyl-1-phenylbutane in urine samples: in vitro-in vivo correlation of metabolic profiles and development of LC-TOF-MS method.
Kobayashi M; Pelander A; Ketola RA; Leinonen A; Kuuranne T
Drug Test Anal; 2015 Feb; 7(2):89-94. PubMed ID: 24687931
[TBL] [Abstract][Full Text] [Related]
17. "Dilute-and-inject" multi-target screening assay for highly polar doping agents using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for sports drug testing.
Görgens C; Guddat S; Orlovius AK; Sigmund G; Thomas A; Thevis M; Schänzer W
Anal Bioanal Chem; 2015 Jul; 407(18):5365-79. PubMed ID: 25925859
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS.
Thomas A; Geyer H; Kamber M; Schänzer W; Thevis M
J Mass Spectrom; 2008 Jul; 43(7):908-15. PubMed ID: 18563864
[TBL] [Abstract][Full Text] [Related]
19. Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls.
Sigmund G; Dib J; Tretzel L; Piper T; Bosse C; Schänzer W; Thevis M
Drug Test Anal; 2015; 7(11-12):1057-62. PubMed ID: 26481102
[TBL] [Abstract][Full Text] [Related]
20. Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing.
Tretzel L; Thomas A; Piper T; Hedeland M; Geyer H; Schänzer W; Thevis M
J Pharm Biomed Anal; 2016 May; 123():132-40. PubMed ID: 26896632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
